Chen Yi-Hsin, Chen Chih-Tsung
Department of Nephrology, Taichung Tzu Chi Hospital, Taichung, Taiwan.
School of Medicine, Tzu Chi University, Hualien, Taiwan.
Kidney Med. 2024 May 17;6(7):100840. doi: 10.1016/j.xkme.2024.100840. eCollection 2024 Jul.
Intradialytic hypotension significantly affects patient safety and clinical outcomes during hemodialysis. Despite various pharmacological and nonpharmacological interventions, effective management remains elusive. In this report, we detail a case of intradialytic hypotension in a male patient in his 40s, undergoing hemodialysis with a history of polycystic kidney disease. Eight years ago, the patient underwent bilateral nephrectomy because of a severe cystic infection, after which his systolic blood pressure (BP) persistently remained at 50-70 mm Hg during dialysis sessions. The initial treatment strategy for hypotension included fludrocortisone, midodrine, and prednisolone, leading to a slight temporary increase in BP, which subsequently declined. As the patient's condition deteriorated, the administration of norepinephrine or dopamine became necessary to sustain BP during dialysis. Given the patient's resistance to these treatments, a daily dose of 25 mg of atomoxetine was introduced. Following this treatment, there was a gradual improvement in the patient's vertigo, weakness, and BP. This case illustrates that low-dose atomoxetine can alleviate symptoms and elevate BP in patients experiencing severe intradialytic hypotension during hemodialysis.
透析期间低血压严重影响血液透析患者的安全性和临床结局。尽管采取了各种药物和非药物干预措施,但有效的管理方法仍然难以捉摸。在本报告中,我们详细介绍了一名40多岁男性患者的透析期间低血压病例,该患者患有多囊肾病,正在接受血液透析。八年前,患者因严重的囊性感染接受了双侧肾切除术,此后在透析期间其收缩压(BP)持续维持在50 - 70 mmHg。低血压的初始治疗策略包括氟氢可的松、米多君和泼尼松龙,导致血压略有暂时升高,但随后又下降。随着患者病情恶化,在透析期间必须使用去甲肾上腺素或多巴胺来维持血压。鉴于患者对这些治疗有抵抗性,引入了每日25 mg的托莫西汀剂量。经过这种治疗,患者的眩晕、虚弱和血压逐渐改善。该病例表明,低剂量托莫西汀可缓解血液透析期间发生严重透析期间低血压患者的症状并升高血压。